Grifols (GIFLF) Shares Outstanding (2009 - 2025)
Grifols' (GIFLF) quarterly Shares Outstanding (Entity) came in at $680.5 million in Q4 2025, little changed on a YoY basis from $679.7 million in Q4 2024, and little changed quarter-over-quarter from $679.7 million in Q4 2024.
Analysis
Grifols (GIFLF) Shares Outstanding (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Shares Outstanding (Entity) for 17 consecutive years, with $680.5 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Shares Outstanding (Entity) changed 0.12% year-over-year to $680.5 million; the trailing twelve-month figure through Dec 2025 stood at $680.5 million (changed 0.12% YoY), and the FY2025 full-year result was $680.5 million, changed 0.12% from the prior year.
- Shares Outstanding (Entity) steadied at $680.5 million in Q4 2025 per GIFLF's latest filing, from $679.7 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $681.6 million in Q4 2021 and bottomed at $679.7 million in Q4 2024.
- Historically, Shares Outstanding (Entity) has averaged $680.3 million across 5 years, with a median of $679.8 million in 2022.
- The sharpest annual moves came in 2021 and 2025: Shares Outstanding (Entity) dropped 0.58% in 2021, then increased 0.12% in 2025.
- Over 5 years, Shares Outstanding (Entity) stood at $681.6 million in 2021, then decreased by 0.26% to $679.8 million in 2022, then retreated by 0.01% to $679.8 million in 2023, then dropped by 0.01% to $679.7 million in 2024, then climbed by 0.12% to $680.5 million in 2025.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $680.5 million, $679.7 million, and $679.8 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 540.00 Mn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 1.24 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 253.70 Mn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 102.80 Mn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 61.30 Mn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 398.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 147.70 Mn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 720.78 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 680.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 680.51 Mn |
| Dec 31, 2024 | 679.67 Mn |
| Dec 31, 2023 | 679.76 Mn |
| Dec 31, 2022 | 679.81 Mn |
| Dec 31, 2021 | 681.56 Mn |
| Dec 31, 2020 | 685.52 Mn |
| Sep 30, 2020 | 685.12 Mn |
| Mar 31, 2020 | 685.12 Mn |
| Dec 31, 2019 | 685.12 Mn |
| Sep 30, 2019 | 684.71 Mn |
| Mar 31, 2019 | 684.71 Mn |
| Dec 31, 2018 | 684.71 Mn |
| Sep 30, 2018 | 684.20 Mn |
| Jun 30, 2018 | 684.20 Mn |
| Mar 31, 2018 | 684.20 Mn |
| Dec 31, 2017 | 684.20 Mn |
| Jun 30, 2017 | 683.23 Mn |
| Mar 31, 2017 | 683.23 Mn |
| Dec 31, 2016 | 683.23 Mn |
| Sep 30, 2016 | 683.55 Mn |